Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Range of CR at 450 day mark

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 05, 2023 9:02pm

178 Views

Post# 35382274

RE:RE:RE:Range of CR at 450 day mark

10% more CRs means 10 more patients out of every 100 who get to keep their bladders. Any approval delay will have serious consequences for a substantial number of patients The FDA must realize this. This is a safe treatment and a benefit over existing treatments has been demonstrated. AA has a good chance of benefiting patients and a very small risk of harming them.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide